Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.

Bar J, Ofek E, Barshack I, Gottfried T, Zadok O, Kamer I, Urban D, Perelman M, Onn A.

Lung Cancer. 2019 Dec;138:109-115. doi: 10.1016/j.lungcan.2019.09.025. Epub 2019 Oct 1.

PMID:
31683093
2.

Evaluation of cases of pediatric extrapulmonary tuberculosis: a single center experience.

Kaba Ö, Kara M, Odacılar CA, Kamer İ, Sütçü M, Demir SÖ, Çalışkan E, Törün SH, Salman N, Somer A.

Turk Pediatri Ars. 2019 Jul 11;54(2):86-92. doi: 10.14744/TurkPediatriArs.2019.33239. eCollection 2019.

3.

Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.

Shiran I, Heller E, Jessel S, Kamer I, Daniel-Meshulam I, Navon R, Urban D, Onn A, Bar J.

Clin Lung Cancer. 2017 May;18(3):316-323.e1. doi: 10.1016/j.cllc.2017.01.009. Epub 2017 Feb 2.

PMID:
28237243
4.

Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.

Katanov C, Lerrer S, Liubomirski Y, Leider-Trejo L, Meshel T, Bar J, Feniger-Barish R, Kamer I, Soria-Artzi G, Kahani H, Banerjee D, Ben-Baruch A.

Stem Cell Res Ther. 2015 May 1;6:87. doi: 10.1186/s13287-015-0080-7.

5.

Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha-synuclein in oligodendrocytes.

Tank J, da Costa-Goncalves AC, Kamer I, Qadri F, Ubhi K, Rockenstein E, Diedrich A, Masliah E, Gross V, Jordan J.

Physiol Rep. 2014 Nov 26;2(11). pii: e12209. doi: 10.14814/phy2.12209. Print 2014 Nov 1.

6.

First-Step Results of Children Presenting with Bleeding Symptoms or Abnormal Coagulation Tests in an Outpatient Clinic.

Yıldız İ, Ünüvar A, Kamer İ, Karaman S, Uysalol E, Kılıç A, Oğuz F, Ünüvar E.

Turk J Haematol. 2015 Dec;32(4):338-43. doi: 10.4274/tjh.2013.0370. Epub 2014 May 29.

7.

Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V.

PLoS One. 2013 Apr 22;8(4):e61353. doi: 10.1371/journal.pone.0061353. Print 2013.

8.

TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R.

PLoS One. 2011;6(7):e21650. doi: 10.1371/journal.pone.0021650. Epub 2011 Jul 1.

9.

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.

Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V.

J Exp Med. 2010 Sep 27;207(10):2127-40. doi: 10.1084/jem.20100797. Epub 2010 Aug 9.

10.

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V.

Cell Death Differ. 2011 Feb;18(2):271-81. doi: 10.1038/cdd.2010.94. Epub 2010 Aug 6.

11.

Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer.

Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V.

Mol Cancer Res. 2009 Aug;7(8):1212-23. doi: 10.1158/1541-7786.MCR-09-0073. Epub 2009 Aug 11.

12.

Proapoptotic BID is an ATM effector in the DNA-damage response.

Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L, Haimovich G, Lerenthal Y, Marcellus RC, Gross A.

Cell. 2005 Aug 26;122(4):593-603.

13.
14.

Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability.

Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, Gorodin S, Fishman A, Chajut A, Einat P, Skaliter R, Gudkov AV, Chumakov PM, Feinstein E.

Oncogene. 2002 Sep 5;21(39):6017-31.

15.

Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.

Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R, Feinstein E.

Mol Cell Biol. 2002 Apr;22(7):2283-93.

16.

In vitro application of the comet assay for aquatic genotoxicity: considering a primary culture versus a cell line.

Kamer I, Rinkevich B.

Toxicol In Vitro. 2002 Apr;16(2):177-84. Erratum in: Toxicol In Vitro 2002 Jun;16(3):327.

PMID:
11869880

Supplemental Content

Support Center